[Author(id=1230762411050087308, tenantId=1045748351789510663, journalId=null, articleId=1179775619636044121, orderNo=null, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=null, email=null, emailSecond=null, emailThird=null, correspondingAuthor=null, authorType=null, ext={CN=AuthorExt(id=null, tenantId=null, journalId=1179461544854732862, articleId=1179775619636044121, authorId=1230762411050087308, language=CN, stringName=寇雅真, 韦薇, 程速远, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=null, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=null)]
寇雅真, 韦薇, 程速远.
关于原核表达的治疗类重组蛋白制品中避免使用β-内酰胺类抗生素及抗性基因的思考[J].
中国新药杂志, 2025, 34(06): 579-584 DOI:10.20251/j.cnki.1003-3734.2025.06.004